{"id":"hyaluronidase","rwe":[{"pmid":"41884958","year":"2026","title":"Molecular interplay between sperm and oocyte: a narrative review.","finding":"","journal":"Human reproduction update","studyType":"Clinical Study"},{"pmid":"41881410","year":"2026","title":"Role of HYAL1 on hyaluronan metabolism and the regulation of epidermal tight junction component CLDN1 in HaCaT cells.","finding":"","journal":"Archives of biochemistry and biophysics","studyType":"Clinical Study"},{"pmid":"41878555","year":"2026","title":"Treatment for Filler-Induced Alopecia with Concentrated Growth Factors.","finding":"","journal":"Clinical, cosmetic and investigational dermatology","studyType":"Clinical Study"},{"pmid":"41877604","year":"2026","title":"Dissolving Hyaluronic Acid Filler: The Diffusion Barrier to Hyaluronidase Efficacy.","finding":"","journal":"Journal of cosmetic dermatology","studyType":"Clinical Study"},{"pmid":"41875671","year":"2026","title":"The impact of glycocalyx on partitioning and distribution of basic drugs.","finding":"","journal":"Drug metabolism and disposition: the biological fate of chemicals","studyType":"Clinical Study"}],"_fda":{"id":"199929ae-773d-c474-e063-6394a90ab8bc","set_id":"21fbd12e-4a12-4ad1-ad01-964cd5ec9996","openfda":{"unii":["64R4OHP8T0"],"route":["SUBCUTANEOUS"],"rxcui":["486166","582692"],"spl_id":["199929ae-773d-c474-e063-6394a90ab8bc"],"brand_name":["VITRASE"],"spl_set_id":["21fbd12e-4a12-4ad1-ad01-964cd5ec9996"],"package_ndc":["24208-002-02"],"product_ndc":["24208-002"],"generic_name":["HYALURONIDASE, OVINE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["HYALURONIDASE (OVINE)"],"manufacturer_name":["Bausch & Lomb Incorporated"],"application_number":["BLA021640"],"is_original_packager":[true]},"version":"8","pregnancy":["8.1 Pregnancy Risk Summary Human studies of hyaluronidase as an aid to conception and as an aid to delivery have been conducted without reports of maternal or fetal harm. Non-human animal reproduction studies have not been conducted with VITRASE. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. However, the background risk in the U.S. general population of major birth defects is 2 to 4%, and of miscarriage is 15 to 20%, of clinically recognized pregnancies. Clinical Considerations Hyaluronidase has been used as a component to aid the in vitro fertilization of human eggs. Administration of hyaluronidase during labor was reported to cause no complications; no increase in blood loss or differences in cervical trauma were observed."],"description":["11 DESCRIPTION Hyaluronidase is an endoglycosidase. VITRASE is a preparation of purified ovine testicular hyaluronidase, a protein enzyme. Hyaluronidase is composed of two major glycosylated forms, α and β. The exact chemical structure of this enzyme is unknown. VITRASE (hyaluronidase injection) is supplied as a sterile, non-preserved, clear and colorless 1 mL solution in a single-dose vial for infiltration use, for interstitial use, for intramuscular use, for intraocular use, for peribulbar use, for retrobulbar use, for soft tissue use, or for subcutaneous use. Each mL contains 200 USP units of hyaluronidase with dibasic potassium phosphate (0.36 mg), lactose monohydrate (0.93 mg), monobasic potassium phosphate (0.23 mg), and sodium chloride (9 mg). The solution has a pH of 6.4 to 7.2."],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied VITRASE ® (hyaluronidase injection) is supplied as 200 USP units/mL of sterile, non-preserved, clear and colorless solution in a single-dose, glass vial with a rubber stopper and aluminum seal. Discard unused portion. NDC 24208-002-02: 200 USP units/mL in a single-dose vial (NDC 24208-002-03) available in a carton containing 2 single-dose vials. 16.2 Storage and Handling Protect from light. Store unopened vial in refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze."],"geriatric_use":["8.5 Geriatric Use No overall differences in safety or effectiveness have been observed between elderly and younger adult patients."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of VITRASE have been established in pediatric patients. Use of VITRASE in these patients is supported by evidence from adequate and well-controlled studies. Clinical hydration requirements for children can be achieved through administration of subcutaneous fluids facilitated with VITRASE. The dosage of subcutaneous fluids administered is dependent upon the age, weight, and clinical condition of the patient as well as laboratory determinations. The potential for chemical or physical incompatibilities should be kept in mind [ see Drug Interactions (7) ] . The rate and volume of subcutaneous fluid administration should not exceed those employed for intravenous infusion. For premature infants or during the neonatal period, the daily dosage should not exceed 25 mL/kg of body weight, and the rate of administration should not be greater than 2 mL per minute. During subcutaneous fluid administration, special care must be taken in pediatric patients to avoid overhydration by controlling the rate and total volume of the infusion [see Dosage and Administration (2.2) ] ."],"effective_time":"20240531","pharmacodynamics":["12.2 Pharmacodynamics In the absence of hyaluronidase, material injected subcutaneously spreads very slowly. Hyaluronidase facilitates dispersion, provided local interstitial pressure is adequate to furnish the necessary mechanical impulse. Such an impulse is normally initiated by injected solutions. The rate and extent of dispersion and absorption is proportionate to the amount of hyaluronidase and the volume of solution. The reconstitution of the dermal barrier removed by intradermal injection of hyaluronidase (over a range of 0.002 to 20 Units/mL) to adult humans indicated that at 24 hours the restoration of the barrier is incomplete and inversely related to the dosage of enzyme; at 48 hours the barrier is completely restored in all treated areas. Results from an experimental study, in humans, on the influence of hyaluronidase in bone repair support the conclusion that this enzyme alone, in the usual clinical dosage, does not deter bone healing."],"pharmacokinetics":["12.3 Pharmacokinetics Knowledge of the mechanisms involved in the disappearance of injected hyaluronidase is limited. It is known, however, that the blood of a number of mammalian species including humans brings about the inactivation of hyaluronidase. Studies have demonstrated that hyaluronidase is antigenic; repeated injections of relatively large amounts of this enzyme may result in the formation of neutralizing antibodies."],"adverse_reactions":["6 ADVERSE REACTIONS The following adverse reactions have been identified during post-approval use of hyaluronidase products. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The most frequently reported adverse reactions have been local injection site reactions. Hyaluronidase has been reported to enhance the adverse reactions associated with co-administered drug products. Edema has been reported most frequently in association with hypodermoclysis. Allergic reactions (e.g., urticaria, angioedema) have been reported in less than 0.1% of patients receiving hyaluronidase. Anaphylactic-like reactions following retrobulbar block or intravenous injections have occurred, rarely. Allergic and anaphylactic-like reactions have been reported, rarely. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-553-5340 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch."],"contraindications":["4 CONTRAINDICATIONS VITRASE is contraindicated in patients with known hypersensitivity to hyaluronidase or any other ingredient in the formulation. Discontinue VITRASE if sensitization occurs. Hypersensitivity ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS It is recommended that appropriate references be consulted regarding physical or chemical incompatibilities before adding VITRASE to a solution containing another drug. Furosemide, benzodiazepines and phenytoin are incompatible with hyaluronidase. ( 7.1 ) Hyaluronidase should not be used to enhance the absorption and dispersion of dopamine and/or alpha agonist drugs. ( 7.2 ) Local anesthetics: Hyaluronidase hastens onset and shortens duration of effect, increases incidence of systemic reactions. ( 7.3 ) Large doses of salicylates, cortisone, adrenocorticotropic hormone (ACTH), estrogens or antihistamines: Concomitant use may require larger amounts of hyaluronidase for equivalent dispersing effect. ( 7.4 ) 7.1 Incompatibilities Furosemide, benzodiazepines and phenytoin have been found to be incompatible with hyaluronidase. 7.2 Drug-Specific Precautions Hyaluronidase should not be used to enhance the absorption and dispersion of dopamine and/or alpha agonist drugs. When considering the administration of any other drug with hyaluronidase, it is recommended that appropriate references first be consulted to determine the usual precautions for the use of the other drug. 7.3 Local Anesthetic Agent When hyaluronidase is added to a local anesthetic agent, it hastens the onset of analgesia and tends to reduce the swelling caused by local infiltration, but the wider spread of the local anesthetic solution increases its absorption; this shortens its duration of action and tends to increase the incidences of systemic reaction. 7.4 Salicylates, Cortisone, ACTH, Estrogens, Antihistamines Patients receiving large doses of salicylates, cortisone, adrenocorticotropic hormone (ACTH), estrogens, or antihistamines may require larger amounts of hyaluronidase for equivalent dispersing effect, since these drugs apparently render tissues partly resistant to the action of hyaluronidase."],"mechanism_of_action":["12.1 Mechanism of Action Hyaluronidase is a spreading or diffusing substance, which modifies the permeability of connective tissue through the hydrolysis of hyaluronic acid, a polysaccharide found in the intercellular ground substance of connective tissue, and of certain specialized tissues, such as the umbilical cord and vitreous humor. Hyaluronic acid is also present in the capsules of type A and C hemolytic streptococci. Hyaluronidase hydrolyzes hyaluronic acid by splitting the glucosaminidic bond between C1 of the glucosamine moiety and C4 of glucuronic acid. This temporarily decreases the viscosity of the cellular cement and promotes diffusion of injected fluids or of localized transudates or exudates, thus facilitating their absorption. Hyaluronidase cleaves glycosidic bonds of hyaluronic acid and, to a variable degree, some other acid mucopolysaccharides of the connective tissue. The activity is measured in vitro by monitoring the decrease in the amount of an insoluble serum albumen-hyaluronic acid complex as the enzyme cleaves the hyaluronic acid component."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Hyaluronidase is a spreading or diffusing substance, which modifies the permeability of connective tissue through the hydrolysis of hyaluronic acid, a polysaccharide found in the intercellular ground substance of connective tissue, and of certain specialized tissues, such as the umbilical cord and vitreous humor. Hyaluronic acid is also present in the capsules of type A and C hemolytic streptococci. Hyaluronidase hydrolyzes hyaluronic acid by splitting the glucosaminidic bond between C1 of the glucosamine moiety and C4 of glucuronic acid. This temporarily decreases the viscosity of the cellular cement and promotes diffusion of injected fluids or of localized transudates or exudates, thus facilitating their absorption. Hyaluronidase cleaves glycosidic bonds of hyaluronic acid and, to a variable degree, some other acid mucopolysaccharides of the connective tissue. The activity is measured in vitro by monitoring the decrease in the amount of an insoluble serum albumen-hyaluronic acid complex as the enzyme cleaves the hyaluronic acid component. 12.2 Pharmacodynamics In the absence of hyaluronidase, material injected subcutaneously spreads very slowly. Hyaluronidase facilitates dispersion, provided local interstitial pressure is adequate to furnish the necessary mechanical impulse. Such an impulse is normally initiated by injected solutions. The rate and extent of dispersion and absorption is proportionate to the amount of hyaluronidase and the volume of solution. The reconstitution of the dermal barrier removed by intradermal injection of hyaluronidase (over a range of 0.002 to 20 Units/mL) to adult humans indicated that at 24 hours the restoration of the barrier is incomplete and inversely related to the dosage of enzyme; at 48 hours the barrier is completely restored in all treated areas. Results from an experimental study, in humans, on the influence of hyaluronidase in bone repair support the conclusion that this enzyme alone, in the usual clinical dosage, does not deter bone healing. 12.3 Pharmacokinetics Knowledge of the mechanisms involved in the disappearance of injected hyaluronidase is limited. It is known, however, that the blood of a number of mammalian species including humans brings about the inactivation of hyaluronidase. Studies have demonstrated that hyaluronidase is antigenic; repeated injections of relatively large amounts of this enzyme may result in the formation of neutralizing antibodies."],"indications_and_usage":["1 INDICATIONS AND USAGE VITRASE is an endoglycosidase indicated as an adjuvant: in subcutaneous fluid administration for achieving hydration. ( 1.1 ) for increasing the dispersion and absorption of other injected drugs. ( 1.2 ) for improving resorption of radiopaque agents, in subcutaneous urography. ( 1.3 ) 1.1 Subcutaneous Fluid Administration (Hypodermoclysis) VITRASE ® (hyaluronidase injection) is indicated as an adjuvant in subcutaneous fluid administration for achieving hydration. 1.2 Dispersion and Absorption of Injected Drugs VITRASE is indicated as an adjuvant to increase the dispersion and absorption of other injected drugs. 1.3 Subcutaneous Urography VITRASE is indicated as an adjuvant in subcutaneous urography for improving resorption of radiopaque agents."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Spread of Localized Infection ( 5.1 ) Ocular Cornea Damage ( 5.2 ) Enzyme Inactivation with Intravenous Administration ( 5.3 ) 5.1 Spread of Localized Infection Hyaluronidase should not be injected into or around infected or acutely inflamed area because of the danger of spreading to a localized infection. Hyaluronidase should not be used to reduce the swelling of bites or stings. 5.2 Ocular Cornea Damage VITRASE should not be applied directly to the cornea. 5.3 Enzyme Inactivation with Intravenous Administration VITRASE should not be used for intravenous injections because the enzyme is rapidly inactivated."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Animal studies have not been conducted to determine whether hyaluronidase has carcinogenic or mutagenic potential. Adequate fertility studies have not been conducted in animals, however, it has been reported that testicular degeneration may occur from the production of organ-specific antibodies against this enzyme following repeated injections."],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Reporting Adverse Reactions Instruct patients to report adverse reactions including redness, swelling, itching, or pain at the injection site. Interactions with Other Medications Instruct patients to report if they are taking furosemide, benzodiazepines, phenytoin, dopamine and/or alpha agonists because these medications have been found to be incompatible with hyaluronidase. Instruct patients to report if they are taking salicylates (e.g., aspirin), steroids (e.g., cortisone or estrogens) or antihistamines because larger amounts of hyaluronidase may be needed to achieve an equivalent dispersing effect. Distributed by: Bausch & Lomb Americas Inc. Bridgewater, NJ 08807 USA Manufactured by: Bausch & Lomb Incorporated Bridgewater, NJ 08807 USA U.S. License Number: 2180 VITRASE is a trademark of Bausch & Lomb Incorporated or its affiliates. © 2023 Bausch & Lomb Incorporated or its affiliates 9427904"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Draw the desired amount of VITRASE into the syringe to obtain target hyaluronidase activity (USP Units) according to table. ( 2.1 ) Before adding VITRASE to a solution containing another drug check appropriate references regarding physical/chemical incompatibilities. ( 7 ) Subcutaneous Fluid Administration : Inject 200 Units of VITRASE prior to clysis. It will facilitate absorption of 1,000 mL or more of solution. The dosage of subcutaneous fluids administered depends upon the age, weight, clinical condition of the patient, and laboratory determinations. Rate and volume of subcutaneous fluid administration should not exceed those employed for intravenous infusion. ( 2.2 , 8.4 ) Increasing absorption and dispersion of injected drugs : Add 50–300 Units (most typically 150 Units) of VITRASE to the injection solution. ( 2.3 ) Subcutaneous urography : With the patient prone, inject 75 Units of VITRASE subcutaneously over each scapula, followed by injection of the contrast medium at the same sites. ( 2.4 ) 2.1 Important Administration Instructions Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. VITRASE should be administered as discussed below, since its effects relative to absorption and dispersion of other drugs are not produced when it is administered intravenously. Draw the desired amount of VITRASE into the syringe to obtain the target Hyaluronidase Activity (USP Units) according to the table below. Table 1. Amount of VITRASE Solution Withdrawn Per Target Hyaluronidase Activity Target Hyaluronidase Activity (USP Units) Volume Withdrawn from Vial (mL) 50 Units 0.25 mL 75 Units 0.38 mL 150 Units 0.75 mL 200 Units 1.00 mL After admixture with drug, store at 15°C to 25°C (59°F to 77°F) and use within 6 hours. Consult the Prescribing Information of other drugs for additional storage information. 2.2 Dosage for Subcutaneous Fluid Administration (Hypodermoclysis) Insert needle with aseptic precautions. With tip free and movable between skin and muscle, begin clysis; fluid should start in readily without pain or lump. Then inject VITRASE into rubber tubing close to needle. An alternate method is to inject VITRASE under skin prior to clysis. 200 Units will facilitate absorption of 1,000 mL or more of solution. As with all parenteral fluid therapy, observe effect closely, with same precautions for restoring fluid and electrolyte balance as in intravenous injections. The dose, the rate of injection, and the type of solution (saline, glucose, Ringer’s, etc.) must be adjusted carefully to the individual patient. When solutions devoid of inorganic electrolytes are given by hypodermoclysis, hypovolemia may occur. This may be prevented by using solutions containing adequate amounts of inorganic electrolytes and/or controlling the volume and speed of administration. VITRASE may be added to small volumes of solution (up to 200 mL), such as small clysis for infants or solutions of drugs for subcutaneous injection. For infants and children less than 3 years old, the volume of a single clysis should be limited to 200 mL; and in premature infants or during the neonatal period, the daily dosage should not exceed 25 mL/kg of body weight; the rate of administration should not be greater than 2 mL per minute. For older patients, the rate and volume of administration should not exceed those employed for intravenous infusion. 2.3 Dosage for Absorption and Dispersion of Injected Drugs Absorption and dispersion of other injected drugs may be enhanced by adding 50 Units to 300 Units, most typically 150 Units of VITRASE to the injection solution. 2.4 Dosage for Subcutaneous Urography The subcutaneous route of administration of urographic contrast media is indicated when intravenous administration cannot be successfully accomplished, particularly in infants and small children. With the patient prone, 75 Units of VITRASE are injected subcutaneously over each scapula, followed by injection of the contrast medium at the same sites."],"spl_product_data_elements":["VITRASE hyaluronidase, ovine MONOBASIC POTASSIUM PHOSPHATE SODIUM CHLORIDE LACTOSE, UNSPECIFIED FORM DIBASIC POTASSIUM PHOSPHATE HYALURONIDASE (OVINE) HYALURONIDASE, OVINE"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Injection: 200 USP Units/mL as a clear, colorless solution in a single-dose vial. Injection: 200 USP units/mL in a single-dose vial ( 3 )"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Pediatric Use: The dosage of subcutaneous fluids administered is dependent upon the age, weight, and clinical condition of the patient. For premature infants or during the neonatal period, the daily dosage should not exceed 25 mL/kg of body weight, and the rate of administration should not be greater than 2 mL per minute. Special care must be taken in pediatric patients to avoid overhydration by controlling the rate and total volume of the infusion ( 2.2 , 8.4 ). 8.1 Pregnancy Risk Summary Human studies of hyaluronidase as an aid to conception and as an aid to delivery have been conducted without reports of maternal or fetal harm. Non-human animal reproduction studies have not been conducted with VITRASE. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. However, the background risk in the U.S. general population of major birth defects is 2 to 4%, and of miscarriage is 15 to 20%, of clinically recognized pregnancies. Clinical Considerations Hyaluronidase has been used as a component to aid the in vitro fertilization of human eggs. Administration of hyaluronidase during labor was reported to cause no complications; no increase in blood loss or differences in cervical trauma were observed. 8.2 Lactation Risk Summary There is no information regarding the presence of VITRASE in human milk, the effects on breastfed infants, or the effects on milk production to inform risk of VITRASE to an infant during lactation. The developmental and health benefits of breastfeeding should be considered, along with the mother’s clinical need for VITRASE, and any potential adverse effects on the breastfed infant from VITRASE. 8.4 Pediatric Use The safety and effectiveness of VITRASE have been established in pediatric patients. Use of VITRASE in these patients is supported by evidence from adequate and well-controlled studies. Clinical hydration requirements for children can be achieved through administration of subcutaneous fluids facilitated with VITRASE. The dosage of subcutaneous fluids administered is dependent upon the age, weight, and clinical condition of the patient as well as laboratory determinations. The potential for chemical or physical incompatibilities should be kept in mind [ see Drug Interactions (7) ] . The rate and volume of subcutaneous fluid administration should not exceed those employed for intravenous infusion. For premature infants or during the neonatal period, the daily dosage should not exceed 25 mL/kg of body weight, and the rate of administration should not be greater than 2 mL per minute. During subcutaneous fluid administration, special care must be taken in pediatric patients to avoid overhydration by controlling the rate and total volume of the infusion [see Dosage and Administration (2.2) ] . 8.5 Geriatric Use No overall differences in safety or effectiveness have been observed between elderly and younger adult patients."],"dosage_and_administration_table":["
Target HyaluronidaseActivity (USP Units)Volume Withdrawn from Vial (mL)
50 Units0.25 mL
75 Units0.38 mL
150 Units0.75 mL
200 Units1.00 mL
"],"package_label_principal_display_panel":["PACKAGE/LABEL PRINCIPAL DISPLAY PANEL – Vitrase Carton Label NDC 24208-002-02 Hyaluronidase Injection Vitrase ® 200 USP Units/mL Derived from ovine testicle Sterile NOT FOR IV USE Rx only BAUSCH+LOMB Two-1 ml Single-Dose Vials. Discard unused portion. 9427704 carton"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Animal studies have not been conducted to determine whether hyaluronidase has carcinogenic or mutagenic potential. Adequate fertility studies have not been conducted in animals, however, it has been reported that testicular degeneration may occur from the production of organ-specific antibodies against this enzyme following repeated injections."]},"tags":[{"label":"Endoglycosidase","category":"class"},{"label":"Biologic","category":"modality"},{"label":"B06AA03","category":"atc"},{"label":"Active","category":"status"},{"label":"Multiple myeloma","category":"indication"},{"label":"Subcutaneous clysis of patient for fluid administration","category":"indication"},{"label":"Systemic AL amyloidosis","category":"indication"},{"label":"Baxter Hlthcare","category":"company"},{"label":"Approved 1950s","category":"decade"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"1377 reports"},{"date":"","signal":"NO ADVERSE EVENT","source":"FDA FAERS","actionTaken":"1020 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"773 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"686 reports"},{"date":"","signal":"RASH","source":"FDA FAERS","actionTaken":"515 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"507 reports"},{"date":"","signal":"ASTHENIA","source":"FDA FAERS","actionTaken":"449 reports"},{"date":"","signal":"PYREXIA","source":"FDA FAERS","actionTaken":"444 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"421 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"396 reports"}],"drugInteractions":[{"drug":"Furosemide","severity":"major","mechanism":"Physical or chemical incompatibility","management":"Do not mix with hyaluronidase","clinicalEffect":"Incompatible with hyaluronidase"},{"drug":"Benzodiazepines","severity":"major","mechanism":"Physical or chemical incompatibility","management":"Do not mix with hyaluronidase","clinicalEffect":"Incompatible with hyaluronidase"},{"drug":"Phenytoin","severity":"major","mechanism":"Physical or chemical incompatibility","management":"Do not mix with hyaluronidase","clinicalEffect":"Incompatible with hyaluronidase"},{"drug":"Dopamine","severity":"major","mechanism":"Enhanced absorption and dispersion","management":"Avoid using hyaluronidase with dopamine","clinicalEffect":"Should not be used to enhance absorption and dispersion"},{"drug":"Alpha agonist drugs","severity":"major","mechanism":"Enhanced absorption and dispersion","management":"Avoid using hyaluronidase with alpha agonist drugs","clinicalEffect":"Should not be used to enhance absorption and dispersion"},{"drug":"Local anesthetics","severity":"moderate","mechanism":"Hastens onset and shortens duration of effect","management":"Monitor for increased systemic effects when used together","clinicalEffect":"Increases incidence of systemic reactions"},{"drug":"Salicylates","severity":"moderate","mechanism":"Reduces effectiveness of hyaluronidase","management":"Increase dose of hyaluronidase if necessary","clinicalEffect":"May require larger amounts of hyaluronidase"},{"drug":"Cortisone","severity":"moderate","mechanism":"Reduces effectiveness of hyaluronidase","management":"Increase dose of hyaluronidase if necessary","clinicalEffect":"May require larger amounts of hyaluronidase"},{"drug":"Adrenocorticotropic hormone (ACTH)","severity":"moderate","mechanism":"Reduces effectiveness of hyaluronidase","management":"Increase dose of hyaluronidase if necessary","clinicalEffect":"May require larger amounts of hyaluronidase"},{"drug":"Estrogens","severity":"moderate","mechanism":"Reduces effectiveness of hyaluronidase","management":"Increase dose of hyaluronidase if necessary","clinicalEffect":"May require larger amounts of hyaluronidase"},{"drug":"Antihistamines","severity":"moderate","mechanism":"Reduces effectiveness of hyaluronidase","management":"Increase dose of hyaluronidase if necessary","clinicalEffect":"May require larger amounts of hyaluronidase"}],"commonSideEffects":[{"effect":"Lagophthalmos","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Parophthalmia","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Purtscher retinopathy","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Conjunctival oedema","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Product administered at inappropriate site","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Exophthalmos","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Deep vein thrombosis postoperative","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Local anaesthetic systemic toxicity","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Myopathy toxic","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Macular ischaemia","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Autoimmune disorder","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Strabismus","drugRate":"LLR 40","severity":"common","_validated":true},{"effect":"Sensory loss","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Intraocular pressure fluctuation","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Electrocardiogram T wave amplitude increased","drugRate":"","severity":"common","_validated":false,"_confidence":0.3}],"contraindications":["VITRASE is contraindicated in patients with known hypersensitivity to hyaluronidase or any other ingredient in the formulation.","Discontinue VITRASE if sensitization occurs."],"seriousAdverseEvents":[{"event":"Allergic reactions (e.g., urticaria, angioedema)","detail":"Reported in less than 0.1% of patients receiving hyaluronidase.","severity":"serious","incidence":"less than 0.1%"}]},"trials":[],"aliases":[],"company":"Baxter","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=HYALURONIDASE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:13:40.121609+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:13:47.191695+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:13:38.760028+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=HYALURONIDASE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:13:47.950317+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:13:37.375459+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:15:12.707169+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:13:37.375480+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:13:49.618669+00:00"},"mechanism.oneSentence":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"12.1 Mechanism of Action Hyaluronidase is a spreading or diffusing substance, which modifies the permeability of connective tissue through the hydrolysis of hyaluronic acid, a polysaccharide found in the intercellular ground substance of connective tissue, and of certain specialized tissues, such as the umbilical cord and vitreous humor. Hyaluronic acid is also present in the capsules of type A and C hemolytic streptococci. Hyaluronidase hydrolyzes hyaluronic acid by splitting the glucosaminidic","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:14:05.463510+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Hyaluronic acid hydrolytic enzyme","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:13:48.624793+00:00"},"safety.drugInteractions":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:15:01.010847+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201636/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:13:48.427801+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"6 ADVERSE REACTIONS The following adverse reactions have been identified during post-approval use of hyaluronidase products. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The most frequently reported adverse reactions have been local injection site reactions. Hyaluronidase has been reported to enhance the adverse reactions associated with co-","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:14:11.611400+00:00"},"safety.contraindications":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:14:18.217685+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"BLA021640","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:13:37.375486+00:00"}},"allNames":"wydase","offLabel":[],"synonyms":["hyaluronidase recombinant human","hyaluronidase","wydase","hyaluronidase ovine","hyaluronidase bovine","vorhyaluronidase alfa (genetical recombination)"],"timeline":[{"date":"1950-03-22","type":"positive","source":"DrugCentral","milestone":"FDA approval (Baxter Hlthcare)"},{"date":"2021-08-25","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Janssen Pharmaceutical, K.K.)"}],"approvals":[{"date":"1950-03-22","orphan":false,"company":"BAXTER HLTHCARE","regulator":"FDA"},{"date":"2021-08-25","orphan":true,"company":"Janssen Pharmaceutical, K.K.","regulator":"PMDA"}],"brandName":"Wydase","ecosystem":[{"indication":"Multiple myeloma","otherDrugs":[{"name":"belantamab mafodotin","slug":"belantamab-mafodotin","company":"Glaxosmithkline"},{"name":"bortezomib","slug":"bortezomib","company":"Millennium Pharms"},{"name":"carfilzomib","slug":"carfilzomib","company":"Onyx Pharms"},{"name":"carmustine","slug":"carmustine","company":"Emcure Pharms Ltd"}],"globalPrevalence":176000},{"indication":"Subcutaneous clysis of patient for fluid administration","otherDrugs":[],"globalPrevalence":null},{"indication":"Systemic AL amyloidosis","otherDrugs":[{"name":"bortezomib","slug":"bortezomib","company":"Millennium Pharms"},{"name":"cyclophosphamide","slug":"cyclophosphamide","company":"Baxter Hlthcare"},{"name":"daratumumab","slug":"daratumumab","company":"Janssen Biotech"},{"name":"dexamethasone","slug":"dexamethasone","company":""}],"globalPrevalence":23200000}],"mechanism":{"target":"hyaluronic acid","novelty":"First-in-class","modality":"Biologic","drugClass":"Endoglycosidase","explanation":"Hyaluronidase works by hydrolyzing hyaluronic acid, a component of connective tissue. This process reduces the viscosity of the tissue, allowing for better diffusion and absorption of injected substances or localized fluids.","oneSentence":"Hyaluronidase increases tissue permeability by breaking down hyaluronic acid, promoting the diffusion and absorption of injected fluids.","technicalDetail":"Hyaluronidase hydrolyzes hyaluronic acid by cleaving the glucosaminidic bond between C1 of the glucosamine moiety and C4 of glucuronic acid. This enzyme also cleaves glycosidic bonds of other acid mucopolysaccharides in the connective tissue, leading to a temporary decrease in tissue viscosity."},"commercial":{"launchDate":"1950","revenueYear":2024,"_launchSource":"DrugCentral (FDA 1950-03-22, BAXTER HLTHCARE)","annualRevenue":900,"revenueSource":"Verified: Halozyme 10-K","revenueCurrency":"USD","revenueConfidence":"verified"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5033","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=HYALURONIDASE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=HYALURONIDASE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:54:21.144859","_validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T00:15:12.974755+00:00","fieldsConflicting":14,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"dornase alfa","drugSlug":"dornase-alfa","fdaApproval":"1993-12-30","relationship":"same-class"},{"drugName":"chymotrypsin","drugSlug":"chymotrypsin","fdaApproval":"1959-07-08","relationship":"same-class"},{"drugName":"trypsin","drugSlug":"trypsin","fdaApproval":"","relationship":"same-class"}],"genericName":"hyaluronidase","indications":{"approved":[{"id":"hyaluronidase-subcutaneous-fluid-administrat","name":"Subcutaneous Fluid Administration","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Not specified","pivotalTrial":null,"restrictions":[],"patientPopulation":"Not specified","diagnosticRequired":null,"brandNameForIndication":"Wydase"},{"id":"hyaluronidase-dispersion-and-absorption-of-i","name":"Dispersion and Absorption of Injected Drugs","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Not specified","pivotalTrial":null,"restrictions":[],"patientPopulation":"Not specified","diagnosticRequired":null,"brandNameForIndication":"Wydase"},{"id":"hyaluronidase-subcutaneous-urography","name":"Subcutaneous Urography","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Not specified","pivotalTrial":null,"restrictions":[],"patientPopulation":"Not specified","diagnosticRequired":null,"brandNameForIndication":"Wydase"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"dornase-alfa","brandName":"dornase alfa","genericName":"dornase alfa","approvalYear":"1993","relationship":"same-class"},{"drugId":"chymotrypsin","brandName":"chymotrypsin","genericName":"chymotrypsin","approvalYear":"1959","relationship":"same-class"},{"drugId":"trypsin","brandName":"trypsin","genericName":"trypsin","approvalYear":"","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT04759586","phase":"PHASE3","title":"Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-05","conditions":["Primary Mediastinal Large B-Cell Lymphoma"],"enrollment":244,"completionDate":"2026-12-31"},{"nctId":"NCT06169215","phase":"PHASE2","title":"Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-23","conditions":["Multiple Myeloma"],"enrollment":70,"completionDate":"2026-09-30"},{"nctId":"NCT05886036","phase":"PHASE2","title":"Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-01-23","conditions":["Nodular Lymphocyte Predominant B-Cell Lymphoma","Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma","Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma"],"enrollment":70,"completionDate":"2026-10-31"},{"nctId":"NCT06948084","phase":"PHASE2","title":"Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-29","conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":80,"completionDate":"2028-02-28"},{"nctId":"NCT05020236","phase":"PHASE3","title":"A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments","status":"RECRUITING","sponsor":"Pfizer","startDate":"2021-10-04","conditions":["Multiple Myeloma"],"enrollment":944,"completionDate":"2027-05-31"},{"nctId":"NCT06337318","phase":"PHASE3","title":"Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-10-23","conditions":["Classic Follicular Lymphoma","Follicular Lymphoma With Unusual Cytological Features"],"enrollment":600,"completionDate":"2032-03-31"},{"nctId":"NCT05256225","phase":"PHASE3","title":"Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-16","conditions":["Endometrial Carcinoma","Endometrial Clear Cell Adenocarcinoma","Endometrial Dedifferentiated Carcinoma","Endometrial Endometrioid Adenocarcinoma","Endometrial Mixed Cell Adenocarcinoma","Endometrial Serous Adenocarcinoma","Endometrial Undifferentiated Carcinoma","Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor"],"enrollment":360,"completionDate":"2027-10-31"},{"nctId":"NCT07388524","phase":"PHASE3","title":"Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-09","conditions":["Lung Non-Small Cell Carcinoma"],"enrollment":336,"completionDate":"2029-09-30"},{"nctId":"NCT07042295","phase":"PHASE2","title":"Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-03-23","conditions":["Locally Recurrent Skin Squamous Cell Carcinoma","Metastatic Skin Squamous Cell Carcinoma"],"enrollment":86,"completionDate":"2029-02-28"},{"nctId":"NCT04998669","phase":"PHASE2","title":"Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma","status":"RECRUITING","sponsor":"Juan P. Alderuccio, MD","startDate":"2022-02-11","conditions":["Follicular Lymphoma"],"enrollment":100,"completionDate":"2030-08-01"},{"nctId":"NCT03267433","phase":"PHASE3","title":"Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2017-11-27","conditions":["Mantle Cell Lymphoma"],"enrollment":689,"completionDate":"2027-01-31"},{"nctId":"NCT07485647","phase":"PHASE2","title":"Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing","status":"NOT_YET_RECRUITING","sponsor":"Eden Biltibo","startDate":"2026-05","conditions":["Multiple Myeloma"],"enrollment":50,"completionDate":"2029-04"},{"nctId":"NCT07484893","phase":"PHASE1","title":"A Study to Evaluate the Safety, PK, and Immunogenicity of Recombinant Human Hyaluronidase in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2026-05-14","conditions":["Healthy Adult Male"],"enrollment":24,"completionDate":"2026-10-24"},{"nctId":"NCT05907759","phase":"PHASE2","title":"Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-10","conditions":["Lymphoma, Primary Effusion"],"enrollment":28,"completionDate":"2035-12-01"},{"nctId":"NCT03301220","phase":"PHASE3","title":"A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2017-11-07","conditions":["Smoldering Multiple Myeloma"],"enrollment":390,"completionDate":"2026-06-30"},{"nctId":"NCT07161414","phase":"PHASE1","title":"A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-25","conditions":["Advanced Solid Tumors"],"enrollment":40,"completionDate":"2029-07-24"},{"nctId":"NCT05388669","phase":"PHASE3","title":"A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-08-05","conditions":["Advanced or Metastatic Non-small Cell Lung Cancer"],"enrollment":418,"completionDate":"2027-06-30"},{"nctId":"NCT05132582","phase":"PHASE3","title":"A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2022-03-07","conditions":["HER2 Positive Breast Cancer"],"enrollment":654,"completionDate":"2027-09-28"},{"nctId":"NCT04802759","phase":"PHASE1,PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-06-22","conditions":["Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer"],"enrollment":316,"completionDate":"2029-05-30"},{"nctId":"NCT06310551","phase":"PHASE1","title":"First Time in Human Study of Long Acting VH4524184 Formulations","status":"RECRUITING","sponsor":"ViiV Healthcare","startDate":"2024-03-21","conditions":["HIV Infections"],"enrollment":268,"completionDate":"2028-01-21"},{"nctId":"NCT07470203","phase":"","title":"Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2026-03-31","conditions":["HER2-positive Breast Cancer"],"enrollment":42,"completionDate":"2029-09-30"},{"nctId":"NCT06142396","phase":"EARLY_PHASE1","title":"Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure","status":"RECRUITING","sponsor":"Augusta University","startDate":"2024-11-01","conditions":["Multiple Myeloma","Renal Failure"],"enrollment":30,"completionDate":"2027-11-01"},{"nctId":"NCT07391670","phase":"PHASE1","title":"A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab","status":"NOT_YET_RECRUITING","sponsor":"AstraZeneca","startDate":"2026-03-31","conditions":["Solid Tumours"],"enrollment":40,"completionDate":"2027-08-30"},{"nctId":"NCT05807048","phase":"PHASE2","title":"Daratumumab in STK11 Mutated NSCLC","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2023-06-01","conditions":["Non-small Cell Lung Cancer With STK11/LKB1 Mutation"],"enrollment":8,"completionDate":"2025-11-11"},{"nctId":"NCT03306615","phase":"PHASE2","title":"Peripheral Modulation of Muscle Stiffness and Spasticity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2021-10-11","conditions":["Muscle Spasticity"],"enrollment":56,"completionDate":"2026-06-30"},{"nctId":"NCT06192979","phase":"NA","title":"Optimize First-line Treatment for AL Amyloidosis With t (11; 14)","status":"RECRUITING","sponsor":"Jin Lu, MD","startDate":"2024-01-05","conditions":["Amyloidosis; Systemic","AL Amyloidosis"],"enrollment":41,"completionDate":"2027-03-31"},{"nctId":"NCT04566328","phase":"PHASE3","title":"Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-02-24","conditions":["Plasma Cell Myeloma","RISS Stage I Plasma Cell Myeloma","RISS Stage II Plasma Cell Myeloma"],"enrollment":1450,"completionDate":"2027-12-31"},{"nctId":"NCT05289687","phase":"PHASE2","title":"Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL","status":"RECRUITING","sponsor":"Eastern Cooperative Oncology Group","startDate":"2023-05-25","conditions":["T-cell Acute Lymphoblastic Leukemia"],"enrollment":20,"completionDate":"2027-06-30"},{"nctId":"NCT07436546","phase":"NA","title":"Prospective Evaluation of Efficacy of Tumescent Steroid Infiltration in Mandibular Third Molar Surgery: a Split Mouth Randomized Study","status":"COMPLETED","sponsor":"Postgraduate Institute of Dental Sciences Rohtak","startDate":"2025-03-23","conditions":["Impacted Third Molar","Impacted Third Molar Tooth","Third Molar Extraction","Third Molar Extraction Surgery"],"enrollment":25,"completionDate":"2025-12-23"},{"nctId":"NCT06718413","phase":"PHASE2","title":"Myofascial Dysfunction in Post Stroke Shoulder Pain","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2025-03-28","conditions":["Stroke"],"enrollment":68,"completionDate":"2028-08-31"},{"nctId":"NCT05593094","phase":"PHASE1,PHASE2","title":"A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-09-03","conditions":["Advanced Solid Tumors","HER2-positive Breast Cancer"],"enrollment":210,"completionDate":"2027-07-31"},{"nctId":"NCT07431827","phase":"PHASE3","title":"MK-3475A±MK-1084 in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)","status":"NOT_YET_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-04-01","conditions":["Non-small Cell Lung Cancer"],"enrollment":400,"completionDate":"2039-10-26"},{"nctId":"NCT06100874","phase":"PHASE2","title":"A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Adrienne G. Waks","startDate":"2023-11-20","conditions":["Her 2 Positive Breast Cancer","Breast Cancer Female","Breast Cancer Metastatic"],"enrollment":28,"completionDate":"2027-11-30"},{"nctId":"NCT04024462","phase":"PHASE3","title":"A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-02-05","conditions":["HER2-positive Early Breast Cancer"],"enrollment":200,"completionDate":"2026-01-19"},{"nctId":"NCT07082270","phase":"PHASE1","title":"Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-04-01","conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":21,"completionDate":"2028-02-01"},{"nctId":"NCT07411950","phase":"NA","title":"EuroPainClinicsStudy IX ( EPCS IX )","status":"COMPLETED","sponsor":"EPC Education s.r.o.","startDate":"2021-01-01","conditions":["Failed Back Surgery Syndrome","Lumbar Radiculopathy","Chronic Low Back Pain","Epidural Fibrosis"],"enrollment":141,"completionDate":"2025-11-30"},{"nctId":"NCT07025330","phase":"PHASE2","title":"A Study of Efgartigimod in Patients With IgG4-Related Disease","status":"RECRUITING","sponsor":"Stanford University","startDate":"2025-11-12","conditions":["IgG4-related Disease"],"enrollment":5,"completionDate":"2028-06-01"},{"nctId":"NCT05415215","phase":"PHASE3","title":"A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2022-07-05","conditions":["Early Breast Cancer","Locally Advanced Breast Cancer","Inflammatory Breast Cancer"],"enrollment":346,"completionDate":"2025-11-07"},{"nctId":"NCT06698042","phase":"PHASE3","title":"A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-11-21","conditions":["Lung Cancer","Non-Small Cell Lung Cancer"],"enrollment":67,"completionDate":"2030-02-11"},{"nctId":"NCT06504394","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-10-14","conditions":["Classical Hodgkin Lymphoma Recurrent","Classical Hodgkin Lymphoma Refractory","Primary Mediastinal Large B-cell Lymphoma Recurrent","Primary Mediastinal Large B-cell Lymphoma Refractory"],"enrollment":66,"completionDate":"2028-11-08"},{"nctId":"NCT07062354","phase":"PHASE2","title":"Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer","status":"NOT_YET_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2026-02","conditions":["Head &Amp; Neck Cancer","Head &Amp; Neck Squamous Cell Carcinoma"],"enrollment":50,"completionDate":"2029-10"},{"nctId":"NCT05730712","phase":"PHASE2","title":"Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2024-03-08","conditions":["Castration-Resistant Prostate Carcinoma","Stage IVB Prostate Cancer AJCC v8"],"enrollment":7,"completionDate":"2025-04-10"},{"nctId":"NCT06350318","phase":"PHASE2","title":"Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-04-19","conditions":["Follicular Lymphoma","Marginal Zone Lymphoma","B-Cell Lymphoma"],"enrollment":43,"completionDate":"2029-03"},{"nctId":"NCT07383441","phase":"PHASE3","title":"Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer","status":"NOT_YET_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2026-06-10","conditions":["Advanced Clear Cell Renal Cell Carcinoma","Metastatic Clear Cell Renal Cell Carcinoma","Stage III Renal Cell Cancer AJCC v8","Stage IV Renal Cell Cancer AJCC v8"],"enrollment":718,"completionDate":"2034-01-31"},{"nctId":"NCT05755035","phase":"PHASE2,PHASE3","title":"A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases","status":"COMPLETED","sponsor":"Takeda","startDate":"2023-10-24","conditions":["Primary Immunodeficiency Diseases (PID)"],"enrollment":65,"completionDate":"2026-01-20"},{"nctId":"NCT05340309","phase":"PHASE2","title":"Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2022-12-07","conditions":["Lung Non-Small Cell Carcinoma","Stage II Lung Cancer AJCC v8","Stage IIA Lung Cancer AJCC v8","Stage IIB Lung Cancer AJCC v8","Stage III Lung Cancer AJCC v8","Stage IIIA Lung Cancer AJCC v8","Stage IIIB Lung Cancer AJCC v8","Stage IIIC Lung Cancer AJCC v8","Stage IV Lung Cancer AJCC v8","Stage IVA Lung Cancer AJCC v8","Stage IVB Lung Cancer AJCC v8"],"enrollment":5,"completionDate":"2027-12-31"},{"nctId":"NCT05232175","phase":"PHASE1","title":"Clinical Study of ALT-BB4 to Determine Tolerance, Safety and Pharmacokinetics in Healthy Volunteer","status":"COMPLETED","sponsor":"Alteogen, Inc.","startDate":"2022-01-18","conditions":["Health, Subjective"],"enrollment":290,"completionDate":"2022-08-24"},{"nctId":"NCT07370233","phase":"PHASE2","title":"Triple Therapy Strategy for Managing Persistent Pain After Spinal Microdiscectomy","status":"COMPLETED","sponsor":"Benha University","startDate":"2023-02-20","conditions":["Spinal Disk Injury"],"enrollment":63,"completionDate":"2025-09-23"},{"nctId":"NCT06747351","phase":"PHASE3","title":"A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-05-06","conditions":["Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)"],"enrollment":59,"completionDate":"2028-06-25"},{"nctId":"NCT05296798","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-07-18","conditions":["Locally Advanced or Metastatic Breast Cancer"],"enrollment":922,"completionDate":"2030-12-31"},{"nctId":"NCT04311606","phase":"PHASE2","title":"Anti-VEGF Therapy for Acute Thyroid Eye Disease","status":"COMPLETED","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2020-11-02","conditions":["Thyroid Eye Disease"],"enrollment":11,"completionDate":"2024-12-17"},{"nctId":"NCT07299955","phase":"PHASE1","title":"A Phase 1 Comparative Study to Evaluate Pharmacokinetics, Immunogenicity, Safety and Tolerability of Bmab3000 and Herceptin Hylecta® After a Single 600 mg SC Injection in Healthy Male Volunteers","status":"NOT_YET_RECRUITING","sponsor":"Biocon Biologics UK PLC","startDate":"2026-01-09","conditions":["Healthy Male Participants"],"enrollment":150,"completionDate":"2026-06-30"},{"nctId":"NCT03467867","phase":"PHASE2","title":"A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Georgetown University","startDate":"2018-04-26","conditions":["Chronic Lymphocytic Leukemia"],"enrollment":25,"completionDate":"2026-12"},{"nctId":"NCT07298746","phase":"NA","title":"Oct Angiography Changes After Local Anesthesia in Cataract Surgery","status":"NOT_YET_RECRUITING","sponsor":"Sohag University","startDate":"2025-12","conditions":["OCTA Changes With Local Anesthesia"],"enrollment":100,"completionDate":"2027-03"},{"nctId":"NCT07294027","phase":"NA","title":"ICSI Versus Conventional IVF in Couples With Unexplained Infertility","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-01-01","conditions":["Unexplained Infertility"],"enrollment":848,"completionDate":"2028-07-30"},{"nctId":"NCT05455697","phase":"PHASE1,PHASE2","title":"Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"University of Washington","startDate":"2023-01-26","conditions":["Diffuse Large B-Cell Lymphoma","Grade 3b Follicular Lymphoma","High Grade B-Cell Lymphoma"],"enrollment":35,"completionDate":"2027-07-06"},{"nctId":"NCT05418868","phase":"PHASE1","title":"A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants","status":"RECRUITING","sponsor":"ViiV Healthcare","startDate":"2022-06-14","conditions":["HIV Infections"],"enrollment":214,"completionDate":"2027-06-08"},{"nctId":"NCT07285239","phase":"PHASE3","title":"Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"PrECOG, LLC.","startDate":"2026-05","conditions":["Multiple Myeloma"],"enrollment":500,"completionDate":"2034-04"},{"nctId":"NCT03281369","phase":"PHASE1,PHASE2","title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-10-13","conditions":["Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma"],"enrollment":214,"completionDate":"2025-10-09"},{"nctId":"NCT07269613","phase":"NA","title":"Pulsed Radiofrequency Versus Hyaluronidase Hydrodissection for Treatment of Carpal Tunnel Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Sohag University","startDate":"2025-12","conditions":["Carpal Tunnel Syndrome (CTS)"],"enrollment":56,"completionDate":"2026-07"},{"nctId":"NCT03735121","phase":"PHASE3","title":"A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-12-27","conditions":["Non-Small Cell Lung Cancer"],"enrollment":438,"completionDate":"2024-11-11"},{"nctId":"NCT07102771","phase":"NA","title":"Efficacy of Hyaluronidase Added to Bupivacaine in Ultrasound-guided Erector Spinae Plane Block in Percutaneous Nephrolithotomy.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kasr El Aini Hospital","startDate":"2025-01-01","conditions":["Erector Spinae Plane Block, Nephrolithotomy, Hyaluronidase"],"enrollment":100,"completionDate":"2025-12-30"},{"nctId":"NCT05084053","phase":"PHASE3","title":"A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2022-01-19","conditions":["Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)","Multifocal Motor Neuropathy (MMN)"],"enrollment":26,"completionDate":"2026-05-31"},{"nctId":"NCT07247097","phase":"PHASE2","title":"ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-04-15","conditions":["Multiple Myeloma","Newly Diagnosed Multiple Myeloma","Transplant Ineligible","Newly Diagnosed Multiple Myeloma (NDMM)"],"enrollment":160,"completionDate":"2035-12-01"},{"nctId":"NCT05511428","phase":"PHASE4","title":"Home Based Daratumumab Administration for Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2022-11-08","conditions":["Plasma Cell Myeloma"],"enrollment":20,"completionDate":"2024-05-22"},{"nctId":"NCT07110844","phase":"PHASE2","title":"Teclistamab-Daratumumab in AL Amyloidosis","status":"RECRUITING","sponsor":"Suzanne Lentzsch, MD","startDate":"2025-11-07","conditions":["Amyloid Light-chain Amyloidosis"],"enrollment":25,"completionDate":"2033-10"},{"nctId":"NCT05513586","phase":"PHASE3","title":"A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants","status":"COMPLETED","sponsor":"Takeda","startDate":"2022-09-13","conditions":["Primary Immunodeficiency Diseases (PID)"],"enrollment":15,"completionDate":"2025-10-31"},{"nctId":"NCT03656718","phase":"PHASE1,PHASE2","title":"A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-10-29","conditions":["Neoplasms by Site"],"enrollment":139,"completionDate":"2024-09-12"},{"nctId":"NCT06212752","phase":"PHASE3","title":"A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-06-13","conditions":["Metastatic Non-small Cell Lung Cancer"],"enrollment":39,"completionDate":"2028-05-22"},{"nctId":"NCT05139225","phase":"PHASE1","title":"A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-10-28","conditions":["Multiple Myeloma"],"enrollment":7,"completionDate":"2026-10"},{"nctId":"NCT06935266","phase":"PHASE1","title":"A Study of TAK-881 With and Without Ramp-Up Dosing in Healthy Adults","status":"COMPLETED","sponsor":"Takeda","startDate":"2025-04-22","conditions":["Healthy Volunteers"],"enrollment":64,"completionDate":"2025-09-22"},{"nctId":"NCT05300451","phase":"PHASE2","title":"Daratumumab in HLA Desensitization Prior to Transplantation","status":"ENROLLING_BY_INVITATION","sponsor":"Barry A. Boilson","startDate":"2022-03-31","conditions":["Cardiac Transplant"],"enrollment":10,"completionDate":"2026-08"},{"nctId":"NCT07220187","phase":"PHASE3","title":"Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial","status":"NOT_YET_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2026-05-02","conditions":["Richter Syndrome","Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma","Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma"],"enrollment":102,"completionDate":"2036-10"},{"nctId":"NCT03590652","phase":"PHASE2","title":"Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"University of California, San Diego","startDate":"2018-10-17","conditions":["Relapsed/Refractory Multiple Myeloma"],"enrollment":23,"completionDate":"2025-07-02"},{"nctId":"NCT05703971","phase":"PHASE1,PHASE2","title":"Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients","status":"RECRUITING","sponsor":"Genprex, Inc.","startDate":"2024-05-09","conditions":["Small Cell Lung Cancer Extensive Stage"],"enrollment":62,"completionDate":"2027-08"},{"nctId":"NCT03500328","phase":"NA","title":"Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2018-05-02","conditions":["Multiple Sclerosis, Relapsing-Remitting"],"enrollment":900,"completionDate":"2026-08-01"},{"nctId":"NCT06046287","phase":"PHASE2","title":"Daratumumab for Polyneuropathy Associated With MGUS","status":"WITHDRAWN","sponsor":"Georgetown University","startDate":"2025-09-26","conditions":["Peripheral Neuropathy","Monoclonal Gammopathy of Undetermined Significance"],"enrollment":0,"completionDate":"2025-09-26"},{"nctId":"NCT06398457","phase":"EARLY_PHASE1","title":"Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2024-09-19","conditions":["Hematologic Malignancy","Bone Marrow Transplant Rejection","Acute Myeloid Leukemia (AML)","Myelodysplastic Syndromes (MDS)","Acute Lymphoblastic Leukemia (ALL), Adult","Multiple Myeloma","Aplastic Anemia","Lymphoma","Non Hodgkin Lymphoma","Hodgkin Lymphoma","Chronic Myeloid Leukemia","Myelofibrosis"],"enrollment":8,"completionDate":"2027-03"},{"nctId":"NCT05671172","phase":"NA","title":"Effect of Adding Hyaluronidase to Bupivacaine in Transversus Abdominis Plane Block for Cesarean Section","status":"COMPLETED","sponsor":"Benha University","startDate":"2023-05-15","conditions":["Pain, Postoperative"],"enrollment":114,"completionDate":"2024-02-10"},{"nctId":"NCT03446040","phase":"PHASE1,PHASE2","title":"An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2018-03-08","conditions":["Advanced Cancer"],"enrollment":92,"completionDate":"2024-08-29"},{"nctId":"NCT06022939","phase":"PHASE3","title":"Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2024-07-01","conditions":["AL Amyloidosis"],"enrollment":338,"completionDate":"2030-10-29"},{"nctId":"NCT04447716","phase":"PHASE1","title":"An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2020-10-16","conditions":["Recurrent B-Cell Non-Hodgkin Lymphoma","Recurrent Follicular Lymphoma","Recurrent Indolent Adult Non-Hodgkin Lymphoma","Recurrent Marginal Zone Lymphoma","Refractory B-Cell Non-Hodgkin Lymphoma","Refractory Follicular Lymphoma","Refractory Indolent Adult Non-Hodgkin Lymphoma","Refractory Marginal Zone Lymphoma"],"enrollment":4,"completionDate":"2027-04"},{"nctId":"NCT05722015","phase":"PHASE3","title":"A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-02-14","conditions":["Metastatic Non-small Cell Lung Cancer"],"enrollment":377,"completionDate":"2028-05-22"},{"nctId":"NCT05498220","phase":"PHASE2","title":"Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2023-02-17","conditions":["Diffuse Large B-cell Lymphoma"],"enrollment":5,"completionDate":"2026-11-07"},{"nctId":"NCT07141589","phase":"NA","title":"Fentanyl Versus Ketorolac as an Adjuvant to Peribulbar Block for Anterior Segment Surgeries","status":"RECRUITING","sponsor":"Cairo University","startDate":"2024-08-25","conditions":["Fentanyl","Ketorolac","Adjuvant","Peribulbar Block","Anterior Segment Surgeries"],"enrollment":168,"completionDate":"2025-11-25"},{"nctId":"NCT07095023","phase":"NA","title":"Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-08-15","conditions":["Breast Cancers"],"enrollment":112,"completionDate":"2029-06-30"},{"nctId":"NCT07085728","phase":"PHASE2","title":"Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure","status":"NOT_YET_RECRUITING","sponsor":"Eastern Cooperative Oncology Group","startDate":"2025-08-11","conditions":["Myeloma Multiple"],"enrollment":74,"completionDate":"2027-02-01"},{"nctId":"NCT06895967","phase":"PHASE1","title":"A Study of TAK-881 and HyQvia in Healthy Adults","status":"COMPLETED","sponsor":"Takeda","startDate":"2025-03-24","conditions":["Healthy Volunteers"],"enrollment":30,"completionDate":"2025-07-24"},{"nctId":"NCT07101016","phase":"NA","title":"Effect of Local Use of Non-steroidal Anti-inflammatory Agent (Diclofenac Sodium) With and Without Hyaluronidase on Post-surgical Pain and Swelling","status":"NOT_YET_RECRUITING","sponsor":"Mariam Hesham Mahmoud Abdelfattah Eissa","startDate":"2025-08-01","conditions":["Root End Resection","Periapical Lesion","Single Rooted Teeth"],"enrollment":44,"completionDate":"2025-08-08"},{"nctId":"NCT07000058","phase":"PHASE2,PHASE3","title":"Wide-Awake Local Anesthesia No Tourniquet (WALANT) With Versus Without Hyaluronidase for Hand Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Misr University for Science and Technology","startDate":"2025-06-20","conditions":["Hand Surgery","Local Infiltration"],"enrollment":100,"completionDate":"2025-12-31"},{"nctId":"NCT06441890","phase":"PHASE2","title":"BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer","status":"RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2024-12-05","conditions":["Breast Cancer","HER2-positive Breast Cancer"],"enrollment":28,"completionDate":"2028-06"},{"nctId":"NCT06713317","phase":"PHASE1","title":"A Phase I Study to Evaluate the Safety and Drug Allergy of HLB3-002 in Healthy Volunteers","status":"COMPLETED","sponsor":"Huonslab Co., Ltd.","startDate":"2024-12-02","conditions":["Healthy"],"enrollment":243,"completionDate":"2025-06-27"},{"nctId":"NCT06439693","phase":"PHASE2","title":"The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-08-08","conditions":["Breast Cancer Female","Breast Cancer","Breast Cancer Metastatic","Estrogen Receptor-positive Breast Cancer","HER2-positive Breast Cancer","Stage IV Breast Cancer"],"enrollment":72,"completionDate":"2033-03-30"},{"nctId":"NCT05561387","phase":"PHASE3","title":"Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2023-10-12","conditions":["Plasma Cell Myeloma"],"enrollment":510,"completionDate":"2031-05-30"},{"nctId":"NCT02519452","phase":"PHASE1","title":"A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-10-22","conditions":["Multiple Myeloma"],"enrollment":120,"completionDate":"2023-04-03"},{"nctId":"NCT06980363","phase":"PHASE1","title":"Hyaluronidase Enzymes and Local Anesthesia","status":"NOT_YET_RECRUITING","sponsor":"Fayoum University","startDate":"2025-06-01","conditions":["Local Infiltration"],"enrollment":20,"completionDate":"2025-08-27"},{"nctId":"NCT06076642","phase":"PHASE3","title":"A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases","status":"RECRUITING","sponsor":"Takeda","startDate":"2024-11-04","conditions":["Primary Immunodeficiency Diseases (PID)"],"enrollment":39,"completionDate":"2029-01-15"},{"nctId":"NCT06955793","phase":"","title":"Expanded Access to TAK-881 for Children and Teenagers With Primary Immunodeficiency Diseases in the USA","status":"AVAILABLE","sponsor":"Takeda","startDate":"","conditions":["Primary Immunodeficiency Diseases (PIDD)"],"enrollment":0,"completionDate":""},{"nctId":"NCT06784843","phase":"NA","title":"Dexmedetomidine Versus Midazolam for Peribulbar Block","status":"COMPLETED","sponsor":"Suez Canal University","startDate":"2023-12-01","conditions":["Cataract"],"enrollment":50,"completionDate":"2024-09-30"},{"nctId":"NCT03277105","phase":"PHASE3","title":"A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-10-27","conditions":["Multiple Myeloma"],"enrollment":522,"completionDate":"2024-01-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Subcutaneous"},"crossReferences":{"NUI":"N0000146371","MMSL":"1312","NDDF":"001887","VUID":"4018028","VANDF":"4018028","RXNORM":"1300478","UMLSCUI":"C0020197","chemblId":"CHEMBL1201636","ChEMBL_ID":"CHEMBL1201636","KEGG_DRUG":"D04456","DRUGBANK_ID":"DB14740","PUBCHEM_CID":"91820602","SNOMEDCT_US":"387280008","MESH_DESCRIPTOR_UI":"D006821"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1950-","companyName":"Baxter Hlthcare","relationship":"Original Developer"},{"period":"2021","companyName":"Janssen Pharmaceutical, K.K.","relationship":"PMDA Licensee"}],"publicationCount":10909,"therapeuticAreas":["Oncology"],"_revenueScrapedAt":"2026-04-08 13:58:52.342898+00","atcClassification":{"source":"DrugCentral","atcCode":"B06AA03","allCodes":["B06AA03"]},"biosimilarFilings":[],"originalDeveloper":"Baxter Hlthcare","recentPublications":[{"date":"2026 Mar 25","pmid":"41884958","title":"Molecular interplay between sperm and oocyte: a narrative review.","journal":"Human reproduction update"},{"date":"2026 Mar 23","pmid":"41881410","title":"Role of HYAL1 on hyaluronan metabolism and the regulation of epidermal tight junction component CLDN1 in HaCaT cells.","journal":"Archives of biochemistry and biophysics"},{"date":"2026","pmid":"41878555","title":"Treatment for Filler-Induced Alopecia with Concentrated Growth Factors.","journal":"Clinical, cosmetic and investigational dermatology"},{"date":"2026 Apr","pmid":"41877604","title":"Dissolving Hyaluronic Acid Filler: The Diffusion Barrier to Hyaluronidase Efficacy.","journal":"Journal of cosmetic dermatology"},{"date":"2026 Mar 2","pmid":"41875671","title":"The impact of glycocalyx on partitioning and distribution of basic drugs.","journal":"Drug metabolism and disposition: the biological fate of chemicals"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Baxter","companyId":"baxter","modality":"Enzyme","firstApprovalDate":"1950","aiSummary":"","enrichmentLevel":4,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1950-03-22T00:00:00.000Z","mah":"BAXTER HLTHCARE","brand_name_local":null,"application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"1950-03-22T00:00:00.000Z","mah":"BAXTER HLTHCARE","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"1950-03-22T00:00:00.000Z","mah":"BAXTER HLTHCARE","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"1950-03-22T00:00:00.000Z","mah":"BAXTER HLTHCARE","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"1950-03-22T00:00:00.000Z","mah":"BAXTER HLTHCARE","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"1950-03-22T00:00:00.000Z","mah":"BAXTER HLTHCARE","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2004-05-05T00:00:00.000Z","mah":"BAUSCH AND LOMB","brand_name_local":null,"application_number":"BLA021640"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2004-10-26T00:00:00.000Z","mah":"AMPHASTAR PHARM","brand_name_local":null,"application_number":"BLA021665"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-02-28T00:00:00.000Z","mah":"GENENTECH INC","brand_name_local":null,"application_number":"BLA761106"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2021-06-10T00:00:00.000Z","mah":"GENENTECH INC","brand_name_local":null,"application_number":"BLA761064"},{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2021-08-25T00:00:00.000Z","mah":"Janssen Pharmaceutical, K.K.","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2026-02-13T00:00:00.000Z","mah":"JANSSEN BIOTECH","brand_name_local":null,"application_number":"BLA761484"},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"EU","regulator":"EMA","status":"application withdrawn","approval_date":null,"mah":null,"brand_name_local":"Vitragan","application_number":"EMEA/H/C/000696"},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vitragan","application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T00:15:12.974755+00:00","fieldsConflicting":14,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}